Cargando…

A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China

This study is the first multi-center non-inferiority study that aims to critically evaluate the effectiveness of HHUS/ABUS in China breast cancer detection. This was a multicenter hospital-based study. Five hospitals participated in this study. Women (30–69 years old) with defined criteria were invi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Yujing, Zhang, Xinyuan, Yang, Yi, Chen, Yi, Wang, Yanan, Zhou, Xiang, Qiao, Youlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260602/
https://www.ncbi.nlm.nih.gov/pubmed/34230562
http://dx.doi.org/10.1038/s41598-021-93350-1
_version_ 1783718842541801472
author Xin, Yujing
Zhang, Xinyuan
Yang, Yi
Chen, Yi
Wang, Yanan
Zhou, Xiang
Qiao, Youlin
author_facet Xin, Yujing
Zhang, Xinyuan
Yang, Yi
Chen, Yi
Wang, Yanan
Zhou, Xiang
Qiao, Youlin
author_sort Xin, Yujing
collection PubMed
description This study is the first multi-center non-inferiority study that aims to critically evaluate the effectiveness of HHUS/ABUS in China breast cancer detection. This was a multicenter hospital-based study. Five hospitals participated in this study. Women (30–69 years old) with defined criteria were invited for breast examination by HHUS, ABUS or/and mammography. For BI-RADS category 3, an additional magnetic resonance imaging (MRI) test was provided to distinguish the true negative results from false negative results. For women classified as BI-RADS category 4 or 5, either core aspiration biopsy or surgical biopsy was done to confirm the diagnosis. Between February 2016 and March 2017, 2844 women signed the informed consent form, and 1947 of them involved in final analysis (680 were 30 to 39 years old, 1267 were 40 to 69 years old).For all participants, ABUS sensitivity (91.81%) compared with HHUS sensitivity (94.70%) with non-inferior Z tests, P = 0.015. In the 40–69 age group, non-inferior Z tests showed that ABUS sensitivity (93.01%) was non-inferior to MG sensitivity (86.02%) with P < 0.001 and HHUS sensitivity (95.44%) was non-inferior to MG sensitivity (86.02%) with P < 0.001. Sensitivity of ABUS and HHUS are all superior to that of MG with P < 0.001 by superior test.For all participants, ABUS specificity (92.89%) was non-inferior to HHUS specificity (89.36%) with P < 0.001. Superiority test show that specificity of ABUS was superior to that of HHUS with P < 0.001. In the 40–69 age group, ABUS specificity (92.86%) was non-inferior to MG specificity (91.68%) with P < 0.001 and HHUS specificity (89.55%) was non-inferior to MG specificity (91.68%) with P < 0.001. ABUS is not superior to MG with P = 0.114 by superior test. The sensitivity of ABUS/HHUS is superior to that of MG. The specificity of ABUS/HHUS is non-inferior to that of MG. In China, for an experienced US radiologist, both HHUS and ABUS have better diagnostic efficacy than MG in symptomatic individuals.
format Online
Article
Text
id pubmed-8260602
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82606022021-07-08 A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China Xin, Yujing Zhang, Xinyuan Yang, Yi Chen, Yi Wang, Yanan Zhou, Xiang Qiao, Youlin Sci Rep Article This study is the first multi-center non-inferiority study that aims to critically evaluate the effectiveness of HHUS/ABUS in China breast cancer detection. This was a multicenter hospital-based study. Five hospitals participated in this study. Women (30–69 years old) with defined criteria were invited for breast examination by HHUS, ABUS or/and mammography. For BI-RADS category 3, an additional magnetic resonance imaging (MRI) test was provided to distinguish the true negative results from false negative results. For women classified as BI-RADS category 4 or 5, either core aspiration biopsy or surgical biopsy was done to confirm the diagnosis. Between February 2016 and March 2017, 2844 women signed the informed consent form, and 1947 of them involved in final analysis (680 were 30 to 39 years old, 1267 were 40 to 69 years old).For all participants, ABUS sensitivity (91.81%) compared with HHUS sensitivity (94.70%) with non-inferior Z tests, P = 0.015. In the 40–69 age group, non-inferior Z tests showed that ABUS sensitivity (93.01%) was non-inferior to MG sensitivity (86.02%) with P < 0.001 and HHUS sensitivity (95.44%) was non-inferior to MG sensitivity (86.02%) with P < 0.001. Sensitivity of ABUS and HHUS are all superior to that of MG with P < 0.001 by superior test.For all participants, ABUS specificity (92.89%) was non-inferior to HHUS specificity (89.36%) with P < 0.001. Superiority test show that specificity of ABUS was superior to that of HHUS with P < 0.001. In the 40–69 age group, ABUS specificity (92.86%) was non-inferior to MG specificity (91.68%) with P < 0.001 and HHUS specificity (89.55%) was non-inferior to MG specificity (91.68%) with P < 0.001. ABUS is not superior to MG with P = 0.114 by superior test. The sensitivity of ABUS/HHUS is superior to that of MG. The specificity of ABUS/HHUS is non-inferior to that of MG. In China, for an experienced US radiologist, both HHUS and ABUS have better diagnostic efficacy than MG in symptomatic individuals. Nature Publishing Group UK 2021-07-06 /pmc/articles/PMC8260602/ /pubmed/34230562 http://dx.doi.org/10.1038/s41598-021-93350-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Xin, Yujing
Zhang, Xinyuan
Yang, Yi
Chen, Yi
Wang, Yanan
Zhou, Xiang
Qiao, Youlin
A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China
title A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China
title_full A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China
title_fullStr A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China
title_full_unstemmed A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China
title_short A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China
title_sort multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260602/
https://www.ncbi.nlm.nih.gov/pubmed/34230562
http://dx.doi.org/10.1038/s41598-021-93350-1
work_keys_str_mv AT xinyujing amulticenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT zhangxinyuan amulticenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT yangyi amulticenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT chenyi amulticenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT wangyanan amulticenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT zhouxiang amulticenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT qiaoyoulin amulticenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT xinyujing multicenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT zhangxinyuan multicenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT yangyi multicenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT chenyi multicenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT wangyanan multicenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT zhouxiang multicenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina
AT qiaoyoulin multicenterhospitalbasedandnoninferioritystudyfordiagnosticefficacyofautomatedwholebreastultrasoundforbreastcancerinchina